Is Johnson and Johnson a risky investment?
Key Points. Johnson & Johnson is one of the top healthcare companies in the world, with a market cap of nearly $400 billion. The company, however, faces an uncertain future because of its unsettled talc lawsuits. The litigation could threaten its dividend and long-term growth prospects.
Is Johnson and Johnson a risky stock?
Overall, the performance of JNJ stock with respect to the index has been quite volatile. Returns for the stock were 9% in 2021, 3% in 2022, and -11% in 2023. In comparison, returns for the S&P 500 have been 27% in 2021, -19% in 2022, and 24% in 2023 — indicating that JNJ underperformed the S&P in 2021 and 2023.
Should you invest in Johnson and Johnson?
Given that JNJ has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Will Johnson and Johnson stock recover?
We estimate Johnson & Johnson's Valuation to be $180 per share, reflecting over 10% upside from its current levels of $158. Our forecast is based on a 17x P/E multiple for JNJ and expected earnings of $10.70 on a per-share and adjusted basis for the full year 2024.
What is the future outlook for Johnson and Johnson?
Johnson & Johnson Stock Forecast
The 14 analysts with 12-month price forecasts for Johnson & Johnson stock have an average target of 166.21, with a low estimate of 40 and a high estimate of 215. The average target predicts an increase of 14.05% from the current stock price of 145.74.
Is Johnson and Johnson financially healthy?
J&J, whose financial results are considered a bellwether for the broader health sector, booked $21.40 billion in total sales for the final three months of 2023, up 7.3% from the same quarter in 2022. The pharmaceutical giant reported net income of $4.13 billion, or $1.70 per share during the quarter.
Which is better to invest in Pfizer or Johnson and Johnson?
PFE's forward EV/Sales multiple of 2.94 is lower than JNJ's 4.35. PFE's forward EV/EBITDA multiple of 8.78x is lower than JNJ's 12.07x. PFE's trailing-12-month levered FCF margin of 8.29% is lower than JNJ's 23.23%. In addition, PFE's trailing-12-month asset turnover ratio of 0.33x is lower than JNJ's 0.48x.
Is Johnson and Johnson stock a good long term investment?
Management guided for more growth in 2024, including adjusted revenue growth of 5.5% and 7.4% earnings growth. It won't make you a millionaire overnight, but Johnson & Johnson's slow and steady excellent performance is highly effective if given enough time to compound.
Why is Johnson and Johnson a good long term investment?
Reasons to buy Johnson & Johnson stock now
These days, J&J has just two operating segments that are both growing much faster than its old consumer health division used to. Last year, J&J reported pharmaceutical revenue that rose 7.2% year over year if you ignore rapidly evaporating sales of its COVID-19 vaccine.
Who is the biggest investor in Johnson and Johnson?
Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VFINX - Vanguard 500 Index Fund Investor Shares, Geode Capital Management, Llc, Morgan Stanley, State Farm Mutual Automobile Insurance Co, Spdr S&p 500 Etf Trust, and ...
What will happen to JNJ shares?
What happens to JNJ stock when the company splits? Once Johnson and Johnson splits, JNJ stock will only give traders and investors exposure to the medical device and pharmaceutical proceeds of the company. The new company, which will be listed as Kenvue, will trade separately.
Is JNJ going to split into two companies?
Johnson & Johnson is splitting into two companies, separating the division that sells Band-Aids and Listerine, from its medical device and prescription drug business. Johnson & Johnson is peeling off a consumer health business that helped it become the world's biggest health care products maker.
What is the 5 year forecast for Johnson and Johnson stock?
Johnson & Johnson stock price stood at $147.59
According to the latest long-term forecast, Johnson & Johnson price will hit $150 by the middle of 2024 and then $200 by the end of 2027. Johnson & Johnson will rise to $250 within the year of 2029 and $300 in 2032.
What is the outlook for Johnson and Johnson in 2024?
Analyst Price Forecast Suggests 23.62% Upside
As of April 17, 2024, the average one-year price target for Johnson & Johnson is 178.96. The forecasts range from a low of 156.55 to a high of $225.75. The average price target represents an increase of 23.62% from its latest reported closing price of 144.77.
Does BlackRock own Johnson and Johnson?
with 9.5% of shares outstanding. BlackRock, Inc. is the second largest shareholder owning 7.7% of common stock, and State Street Global Advisors, Inc. holds about 5.4% of the company stock.
What will JNJ stock price be in 2025?
Johnson & Johnson stock prediction for 1 year from now: $ 121.86 (-15.72%) Johnson & Johnson stock forecast for 2025: $ 152.69 (5.70%)
Is Johnson and Johnson in debt?
Total debt on the balance sheet as of December 2023 : $29.33 B. According to Johnson & Johnson's latest financial reports the company's total debt is $29.33 B. A company's total debt is the sum of all current and non-current debts.
Why are J&J shares down?
Shares of Johnson & Johnson (JNJ 0.46%) were sliding today as the diversified healthcare company edged past estimates in its fourth-quarter earnings report, but agreed to pay $700 million to settle lawsuits saying that its talc-based baby powder caused cancer.
Who is Johnson and Johnson biggest competitor?
The main competitors of Johnson & Johnson include Merck & Co., Inc. (MRK), AbbVie (ABBV), Pfizer (PFE), Bristol-Myers Squibb (BMY), Eli Lilly and Company (LLY), AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), and Sanofi (SNY).
Which company is bigger Pfizer or Johnson & Johnson?
J&J's $94.9 billion in 2022 sales placed it behind only Pfizer, also among the world's largest pharmaceutical companies. Of course, J&J's figure includes revenues from its medical devices and consumer healthcare units, so it's not a direct comparison to some of the other top dogs in the biopharma world.
How is Johnson and Johnson different from Pfizer?
The Pfizer and Moderna vaccines are made using messenger RNA, or mRNA, a technology that delivers a bit of “genetic code” to cells to produce the surface spike protein. The J&J vaccine uses a harmless adenovirus vector engineered to carry the “genetic code” for the surface spike protein.
Is Johnson and Johnson a competitor to Pfizer?
Pfizer is one of the leading companies in the biotechnology and pharmaceutical industry. Pfizer's top-selling drugs in FY 2022 were Paxlovid and Eliquis. Pfizer's main competitors are Johnson & Johnson, Novo Nordisk A/S, Roche Holding AG, Eli Lilly and Co., AbbVie Inc., and Merck & Co.
What are the safest stocks to buy long term?
| Stock | Sector | Trailing 12-month dividend yield* |
|---|---|---|
| International Business Machines Corp. (ticker: IBM) | Technology | 3.6% |
| Abbott Laboratories (ABT) | Health care | 1.9% |
| Stanley Black & Decker Inc. (SWK) | Industrials | 3.5% |
| Atmos Energy Corp. (ATO) | Utilities | 2.7% |
Is JNJ stock recession proof?
With decades of dividend increases and a strong and diversified business model, Johnson & Johnson (NYSE:JNJ) ranks seventh in our list of the best stocks to buy before recessions.
Is JNJ undervalued?
Intrinsic Value. The intrinsic value of one JNJ stock under the Base Case scenario is 158.1 USD. Compared to the current market price of 144.32 USD, Johnson & Johnson is Undervalued by 9%.
